Want to see XXII full AI Analyst Report?
XXII Stock Chart & Stats
$4.27
-$0.13(-3.04%)
At close: 4:00 PM EDT
$4.27
-$0.13(-3.04%)
Day’s Range― - ―
52-Week Range$3.61 - $801.00
Previous Close$3.97
Volume14.18K
Average Volume (3M)2.49M
Market Cap
$1.38M
Enterprise Value-$6.91
Total Cash (Recent Filing)$9.54M
Total Debt (Recent Filing)$1.32M
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-214.80
Shares Outstanding345,124
10 Day Avg. Volume328,967
30 Day Avg. Volume2,485,312
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.70
Price to Sales (P/S)6.03
P/FCF Ratio-4.95
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-18
Revenue Forecast (FY)$32.50M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityA materially reduced debt load and positive equity provide durable financial flexibility. Low leverage lowers bankruptcy and interest risk, giving management room to fund commercialization, marketing hires, or bridge near-term losses without urgent refinancing, supporting execution over the next 2–6 months.
Regulatory Differentiation (FDA Authorization)Having the only FDA-authorized product of its kind is a structural competitive advantage. Regulatory validation supports science-based positioning, retailer acceptance, and policy discussions, raising barriers to entry and helping sustain differentiated demand as the company scales distribution and marketing.
Distribution Wins And Retail Scale PlanConcrete retail placements and a >5,000 outlet target create durable revenue runway if executed. Broader retail coverage improves unit economics, increases brand visibility, and enables marketing leverage and merchandising scale that can materially improve gross results over several quarters.
Bears Say
Negative Gross Profit And Operating LossesPersistent negative gross profit means the core product economics are loss-making today. Operating losses force reliance on financing and limit reinvestment ability; until gross margins turn positive, sustained profitability and free-cash-flow generation remain uncertain over the next few quarters.
Ongoing Cash Burn And Negative Operating Cash FlowMaterial negative operating and free cash flow creates structural financing risk. Even with improved metrics, the company must access capital markets or use balance-sheet resources to fund operations and distribution investments, constraining strategic optionality and raising dilution or runway concerns.
Contract Manufacturing Termination RiskLosing a manufacturing customer reduces utilization and contract revenue, pressuring near-term volumes and margins. The company must replace capacity or find new customers; failure to do so could worsen unit economics and complicate the planned retail and marketing investments over the coming months.
22nd Century News
XXII FAQ
What was 22nd Century’s price range in the past 12 months?
22nd Century lowest stock price was $3.61 and its highest was $801.00 in the past 12 months.
What is 22nd Century’s market cap?
22nd Century’s market cap is $1.38M.
When is 22nd Century’s upcoming earnings report date?
22nd Century’s upcoming earnings report date is Aug 19, 2026 which is in 16 days.
How were 22nd Century’s earnings last quarter?
22nd Century released its earnings results on May 07, 2026. The company reported -$101.4 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is 22nd Century overvalued?
According to Wall Street analysts 22nd Century’s price is currently Overvalued.
Does 22nd Century pay dividends?
22nd Century does not currently pay dividends.
What is 22nd Century’s EPS estimate?
22nd Century’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 22nd Century have?
22nd Century has 345,124 shares outstanding.
What happened to 22nd Century’s price movement after its last earnings report?
22nd Century reported an EPS of -$101.4 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -16.344%.
Which hedge fund is a major shareholder of 22nd Century?
Currently, no hedge funds are holding shares in XXII
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
22nd Century
22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
XXII Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed cautious optimism: management reported clear early commercial progress with sequential revenue growth, gross loss improvement, strategic retail distribution wins, regulatory validation (FDA authorization) and a stable cash position. However, material challenges remain — operating losses and negative adjusted EBITDA widened, profitability is below targets, low-margin contracts persist, and retail adoption is uneven. Management plans focused investments in marketing and distribution with a target of ~5,000 outlets by year-end, but execution risk and competitive headwinds mean near-term results may continue to be pressured.View all XXII earnings summariesTechnical Analysis
Universal
―
Turning Point Brands
―
Greenlane Holdings
―
Kaival Brands Innovations Group
―
Ispire Technology, Inc.
―
Ownership Overview
73.39% Insiders
1.35% Mutual Funds
― Other Institutional Investors
25.26% Public Companies and
Individual Investors